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ABSTRACT  
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic 
detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine 
kinase is frequently overexpressed in cancers leading to uncontrolled receptor activation 
and signaling. A combination of HER2 targeting monoclonal antibodies shows greater 
anticancer efficacy than the single targeting antibodies, however, its mechanism of action 
is largely unclear. Here we report novel actions of anti-HER2 drugs, Trastuzumab and 
Pertuzumab, involving NRF2. 
HER2 targeting by antibodies inhibited growth in association with persistent generation 
of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction in NRF2 levels 
and inhibition of NRF2 function in ovarian cancer cell lines. The combination of 
antibodies produced more potent effects than single antibody alone; downregulated NRF2 
substrates by repressing the Antioxidant Response (AR) pathway with concomitant 
transcriptional inhibition of NRF2. We showed the antibody combination produced 
increased methylation at the NRF2 promoter consistent with repression of NRF2 
antioxidant function, as HDAC and methylation inhibitors reversed such produced 
transcriptional effects. These findings demonstrate a novel mechanism and role for NRF2 
in mediating the response of cancer cells to the combination of Trastuzumab and 
Pertuzumab and reinforce the importance of NRF2 in drug resistance and as a key 
anticancer target.  
Key words: Pertuzumab/Trastuzumab, NRF2, ROS, HER2-targeted, Cancer-
Immunotherapeutics.  
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INTRODUCTION 
 
Nuclear erythroid related factor-2 (NRF2) is a leucine zipper transcription factor 
and the master regulator of the antioxidant response (AR) pathway. It drives both basal 
and oxidative stress-induced transcription of a battery of phase I, II, and III detoxification 
enzymes and cytoprotective genes [1-3], as well as other genes of the metabolic and 
signal transduction pathways [2-4]. This is achieved by its binding to cis-acting factors 
called Antioxidant Response Elements (AREs) or electrophile response elements 
(EpREs) within the promoters of its target genes [5]. Under basal conditions, a low level 
of free NRF2 is available in the cytoplasm where some translocates into the nucleus to 
drive the basal transcription of target genes. Much of the remaining cytosolic NRF2 is 
held by Kelch-like ECH-associated protein 1 (KEAP1), a cytoplasmic NRF2-binding 
adaptor that primes NRF2 for degradation via 26S proteasome [6, 7]. Following oxidative 
stress or in the presence of NRF2 activators, a number of cysteine residues within 
KEAP1 become oxidized causing conformational changes in the KEAP1 structure. This 
disables KEAP1 to bind additional NRF2 and cause its degradation leading to nuclear 
accumulation of NRF2, activation of its transcriptional function to induce transactivation 
of ARE-containing genes and finally restoration of cellular redox homeostasis [8].  
 
Hyperactivation of NRF2 is also a recognized intermediate in cellular 
proliferation and in conferring therapeutic resistance to cancers [9-11]. Specifically, 
NRF2 activation and KEAP1 inactivation mutations are harbinger to permanent 
constitutive activation of the NRF2 dependent AR pathway now frequently observed in 
4 
 
cancers [12-15]. Furthermore, several therapeutic strategies such as anticancer radio- and 
chemo-therapy largely depend on reactive oxygen species (ROS) generation to induce 
cytotoxicity. Thus, hyper-activation of NRF2 dependent AR pathway would attenuate the 
potency of such agents. Moreover, NRF2 is directly involved in the regulation of 
apoptosis and proliferation [16, 17]. 
The HER receptor network contains four members (HER1, HER2, HER3 and 
HER4) belonging to the family of Receptor Tyrosine Kinases (RTKs), which are key 
regulators of cellular proliferation, differentiation and survival [18-21]. Activation of 
RTKs involves ligand dependent homo- and hetero-dimerization and stimulation of their 
intrinsic tyrosine kinase activity that leads to the phosphorylation of tyrosine residues in 
the intracellular domain of these receptors. The phospho-tyrosine residues serve as 
docking sites to recruit a number of signal adapter proteins containing specific domains 
called SH2- and PTB. Through these domains, RTK links its activation with different 
cellular signaling pathways such as PI3K/AKT/mTOR, MAPK, and STAT [22, 23]. The 
activation kinetics and strength of the HER receptor network depend significantly on the 
expression levels, which vary across different cells and cancers [24]. Likewise it is these 
variations in expression combined with their context dependent preferences for 
dimerization partners and ligand dependent or independent signaling modes that cause 
complexity in fully elucidating the activation and functioning of the HER receptor 
family.  
The HER2 and HER3 receptors are non-autonomous and possess certain defining 
features, in that HER2 has auto-kinase activity but no known ligands, whereas HER3 is a 
pseudo-kinase receptor that lacks tyrosine kinase activity. These features dictate the 
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interaction between the HER2 and HER3 receptors and for forming active heterodimer 
complexes. Mutation or increased gene copy number leads to hyper-activation or 
overexpression of HER receptors respectively. These mechanisms lead to receptor auto-
phosphorylation and constitutive activation, enabling cells to lose their requirement for 
ligand and/or hetero-dimerization of receptors, mechanisms which elicit uncontrolled 
proliferative pathways ultimately converting normal cells into malignant cells [18, 22, 23, 
25, 26]. Among the RTK kinase family members, HER2 has gained major importance as 
an anticancer drug target. This is owing to this receptor frequently being overexpressed in 
certain cancer types and partners with the HER3 receptor, a combination, which is known 
to strongly elicit robust growth-promoting pathways [27-33].  
HER2 targeting immunotherapeutic agents, comprising of HER2 specific 
humanized monoclonal antibodies, Pertuzumab and Trastuzumab (Herceptin), have 
acquired a central position as targeted anticancer modalities and are currently being 
extensively studied [31, 32]. These monoclonal antibodies frequently have limited 
effectiveness in combating cancers as tumor cells circumvent the action of the single 
agents due to the readjustments in co-expression of HER2/HER3 receptors, their ligand 
binding dynamics or changing preference for the dimerizing partners [25, 34, 35]. 
Because of such complexity, it is imperative to identify and characterize downstream 
pathway nodes where RTK signaling converges, in order to identify novel druggable 
targets to exploit during immunotherapies involving HER2 inhibition.  
 
 Recently, a growing body of evidence has implicated coregulatory roles of 
HER2/HER3, NRF2 and ROS in the promotion of cellular proliferation, increased 
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detoxification potential and therapeutic resistance in cancer cells [36-39]. Specifically, 
generation of ROS, which is a key regulator of the NRF2 pathway [40], has been 
demonstrated as a regulator of the HER2/HER3 complex and subsequent activation of 
their functions [41]. Elucidation of these new mechanisms place ROS at a central position 
where it might act as a point of convergence of these two cytoprotective pathways. 
Moreover, studies have also shown direct mechanisms of activation of NRF2 by 
components of the RTK pathway such as PI3K and MAPK [42, 43], whereas many 
aspects of RTK signaling are regulated by ROS, whose levels are directly modulated by 
NRF2 function [44]. We have recently shown that NRF2 regulates the expression of 
HER2 and HER3 to modulate HER2/HER3 targeted immunotherapy against ovarian 
cancer cells [45]. We have also shown the ROS-dependent hierarchical addiction and 
manipulation strategy of these cancer cells to draw proliferative advantage [10, 11]. This 
led us to hypothesize that inhibition of NRF2 function and concomitant cellular 
accumulation of ROS are possible mechanistic components and basis of action of HER2-
targeted immunotherapy. 
 
In this study, we have elucidated a new mechanism of action of the combination 
of anticancer immunotherapeutic agents. We demonstrate that combination treatment 
with HER2 targeting monoclonal antibodies, Pertuzumab and Trastuzumab, causes 
inhibition of NRF2 function and subsequent repression of NRF2 dependent antioxidant 
response pathway in human ovarian cancer cell lines. This repressive action on NRF2 not 
only defined the overall sensitivity towards targeted therapy, but could also be modulated 
to further enhance this sensitivity in otherwise resistant ovarian cancer cells. 
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Furthermore, we present evidence and describe an epigenetic mechanism of 
transcriptional repression of NRF2, which involves promoter methylation and gene 
silencing following combination of Pertuzumab and Trastuzumab treatment. Thus we 
reveal that the effectiveness and enhanced cytotoxic action of the combination of HER2 
targeted immunotherapeutic agents can be at least partly explained by their ability to 
cause transcriptional inhibition of NRF2 and greater repression of its antioxidant function 
in low, moderate and high HER2 expressing ovarian cancer cell lines. As such, this study 
expands the role of NRF2 as a key element in driving drug resistance and offers a novel 
strategy of cancer cell sensitization during the course of targeted therapy for cancer 
employing immunotherapeutics.  
 
RESULTS 
 
Action of targeted immunotherapeutic agents involves generation of ROS, which 
contributes to cancer growth inhibition. 
 
Reactive oxygen species (ROS), while traditionally considered as cellular by-
products of metabolism, have gained enormous importance in the past decade and are 
further recognized as second messengers in signal transduction processes influencing 
growth, survival and overall physiological homeostasis [46-48]. Furthermore, there are 
several previous studies that have illustrated the co-modulatory role and interaction of 
ROS with RTK receptors and growth promoting pathways [49-52]. These taken together 
with our recent work (10, 11, 45) have led us to hypothesize that inhibition of NRF2 
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function and concomitant cellular accumulation of ROS are possible mechanistic 
components and basis of action of HER2-targeted immunotherapy. To address this 
hypothesis we first studied total ROS levels in basal, Heregulin (HRG) stimulated and 
drug-inhibited states in three cell lines. HRG is a growth factor belonging to the EGF 
family. We used HRG as it is a potent ligand for HER receptors and causes HER2-HER3 
dimerization [20]. We used a low HER2 expressing ovarian cancer cell line, OVCAR4, a 
moderately HER2 expressing PEO4 and a HER2 overexpressing cell line, SKOV3 [34]. 
 
Data in Figure 1A illustrate that HRG stimulation alone led to a significant and sustained 
increase in ROS levels in all three cell lines as compared to basal levels in unstimulated 
cells. More importantly, we saw that treatments with Pertuzumab, Trastuzumab or their 
combination led to ROS generation in our ovarian cancer cell line models. ROS elevation 
was seen at all the time points tested but these were consistently significant in PEO4 cells 
and more restricted in OVCAR4 (Figure 1B). Within single agent treatments, in PEO4, 
Pertuzumab generated more ROS than Trastuzumab while in OVCAR4 and SKOV3, 
Trastuzumab consistently generated higher ROS than Pertuzumab alone.  
 
We then further investigated the contribution of ROS generation in the 
mechanism of cytotoxic action of these immunotherapeutic agents. To address this, we 
repeated our cytotoxicity experiment but this time co-treated cells with the ROS 
scavenger, N-acetyl Cysteine (NAC) in order to neutralize ROS and then study its 
consequences on survival for different time points of treatment. Strikingly, we found that 
neutralization of ROS in all the cell lines significantly improved survival following drug 
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treatments (Figure 1C), especially at later time point and perhaps following the uptake 
and channeling of NAC in de novo GSH synthesis. Consistent with our previous 
conclusions, NAC dependent protection was more pronounced and sustained in the PEO4 
cell line and with Pertuzumab and combination treatments, whereas for OVCAR4, NAC 
was more protective following Trastuzumab and combination treatment. Interestingly, 
NAC treatment of SKOV3 cells exerted limited protection against cytotoxic action of the 
inhibitors (Figure 1C). These observations are of significance, as they clearly illustrate 
the role of ROS and hence of the overall antioxidant potential of cancer cells in 
determining sensitivity to otherwise unrelated immunotherapeutic agents. The fact that 
receptor inhibition led to generation of ROS (Figure 1B) and that this ROS was a 
contributing factor in cellular cytotoxicity (Figure 1C) implicated the engagement of 
antioxidant pathway during drug action. . Thus, we next sought to investigate the status 
of the NRF2-KEAP1antioxidant response of these cancer cells following the 
HER2/HER3 targeted immunotherapies. In order to further support and confirm this role, 
we performed additional experiments as described below.  
 
Inhibition of NRF2 by Retinoic acid (RA) disrupts its antioxidant transcriptional 
program, suppresses NRF2 and HO-1 protein levels, elevates cellular ROS and 
enhances cytotoxicity of the immunotherapeutic agents.  
 
Retinoic acid (RA) has previously been shown to inhibit the antioxidant response 
(AR) pathway in an NRF2 dependent manner [53]. In order to extend the observations 
reported in the previous section, we wanted to study the consequences of NRF2 inhibition 
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on survival following exposure to the HER2 targeting drugs. Firstly, we did a series of 
experiments in the ovarian cancer cell line models in order to validate and confirm the 
inhibitory action of RA on the NRF2 dependent AR pathway. Exposure to RA alone 
caused a decrease in total NRF2 levels (Figure 2A). Interestingly the levels of NRF2 in 
these cell lines were further decreased following co-treatment with combined 
immunotherapy (Trastuzumab & Pertuzumab). This drug induced reduction in NRF2 
levels suggested that immunotherapy is also targeting NRF2. Next, using the luciferase 
ARE reporter AREc32 cell line, we demonstrated that RA treatment significantly 
inhibited transcriptional activity of NRF2 at all the time points tested (Figure 2B). RA 
treatment of AREc32 reporter cell line also elevated ROS levels (Figure S1). 
Furthermore, RA could not further enhance the inhibitory action of combination of 
immunotherapeutic agents on AR pathway. We also examined the effect of RA treatment 
at single cell level on NRF2 substrate, HO-1,and could demonstrate a decrease in its 
abundance (Figure 2C). These findings suggested that while RA inhibits NRF2 dependent 
AR pathway, such treatment might also elevate cellular ROS levels in the ovarian cancer 
cell lines. Indeed we found that treatment with RA significantly induced ROS in the three 
cell lines tested (Figure 3A&B).  
 
We next asked whether RA dependent inhibition of NRF2 AR pathway would 
sensitize ovarian cancer cells to targeted immunotherapeutic agents and if such treatment 
could achieve sensitization in the otherwise drug resistant OVCAR4 cell line. To do this, 
we repeated drug treatments either alone or in combination for 24-96 h, but this time with 
co-treatment of RA (Figure 3C). We found significantly enhanced cytotoxicity of 
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targeted therapies following NRF2 inhibition in all three cell lines, in all treatments and 
at most time points tested. PEO4 cell line was most sensitized to such treatments with all 
groups showing significant increase in cell death. OVCAR4, which was more resistant, 
was also sensitized to targeted therapies following RA treatment. We also determined 
whether treatment with RA in the absence of any other drugs alone could curb cancer 
growth, and thus analyzed growth rates for 4 days and found growth inhibition (Figure 
S2). These findings illustrated the important role of NRF2 in influencing outcomes to 
targeted therapies involving HER2 receptor inhibition.  
 
 These results indicate that effectiveness of anticancer therapy involving targeted 
immunotherapeutic agents could be enhanced by parallel inhibition of the NRF2 
dependent antioxidant response pathway. As such, this represents a novel drug target in 
the context of HER2 inhibition and could explain the enhanced effectiveness of 
combination of Pertuzumab and Trastuzumab, a treatment that reduced NRF2 levels, as 
opposed to single agents. This could further serve to explain why HER2 
immunotherapeutics in certain contexts show poor efficacy.  
 
Action of targeted immunotherapeutic agents involves repression of NRF2-dependent 
transcription and depletion of total Glutathione.  
 
Having observed additional decreased levels of NRF2 in these cell lines following 
combined immunotherapy (Trastuzumab & Pertuzumab) with RA treatments, we next 
asked whether targeted immunotherapy would also inhibit NRF2-dependent transcription. 
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To address this, we used the AREc32 cell line, stably expressing 8 copies of NRF2 
dependent cis-regulatory antioxidant response elements, as a luciferase reporter. We 
found that while HRG stimulation alone induced the antioxidant response pathway, , co-
treatment with combination of Pertuzumab and Trastuzumab not only disrupted such 
induction, but further suppressed it significantly at 24 and 72 h of treatment (Figure 4A). 
Treatments with single agents alone also inhibited NRF2 function, although to a lesser 
extent than their combination.  
 
 We next asked whether NRF2 repression would also lead to depletion of total 
cellular glutathione. A 96 h treatment with HRG induced total cellular glutathione, while 
combination of Pertuzumab and Trastuzumab significantly reduced this level in PEO4 
cells. The same was seen for OVCAR4 and SKOV3 cells, albeit not significantly (Figure 
4B). These studies demonstrate that HER2 targeting monoclonal antibodies repress the 
NRF2 dependent antioxidant pathway which may well contribute to the unique enhanced 
cytotoxicity in the combination of Pertuzumab and Trastuzumab.  
 
Ovarian cancer cells exhibit different degrees of cytotoxicity to HER2 targeting 
immunotherapeutic agents Pertuzumab and Trastuzumab.  
 
We next determined the degree of sensitivity of ovarian cancer cells derived from 
different origins to the HER2 targeting monoclonal antibodies, Pertuzumab and 
Trastuzumab, either used individually or in combination (Figure 5A). To do this, we 
again used the low HER2 expressing ovarian cancer cell line, OVCAR4, the moderately 
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HER2 expressing PEO4 and the HER2 overexpressing cell line, SKOV3 [34]. Moreover, 
the expression of the HER2 key heterodimerization partner, HER3, is variable in these 
ovarian cell lines with PEO4 expressing the highest, OVCAR4 moderate and SKOV3, the 
lowest [34]. We found that not only did the cells exhibit variable and statistically 
significant and distinct susceptibilities to the monoclonal antibodies, but that they also 
exhibited time dependent variation in sensitivities (Figure 5A). For example, within 
single treatments, while Pertuzumab was more cytotoxic (than Trastuzumab) to PEO4 
cells, Trastuzumab achieved greater cytotoxicity in OVCAR4 and SKOV3 cell lines. 
Secondly, with each treatment modality, growth inhibition was maximal following 72 h 
of treatment. Thirdly, the combination treatment, having both Pertuzumab and 
Trastuzumab, was generally more cytotoxic than single agents in all cell lines. Finally, 
overall, PEO4 was found to be more sensitive to combination of the drugs, SKOV3 
showed moderate sensitivity while OVCAR4 was least sensitive (Figure 5A).  
 
 This analysis revealed the differential responses of the tested ovarian cancer cell 
lines to the same HER2 inhibitors indicating the variable nature of outcomes to targeted 
therapy involving HER2 inhibitors. However, since most of the time points tested 
revealed the combination of the two inhibitors produced the highest growth inhibition, 
this initial cytotoxicity data supports the use of the combination treatment in ovarian 
cancer [31, 33]. 
 
Pertuzumab and Trastuzumab produce different levels of RTK signaling inhibition in 
ovarian cancer cell lines.  
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Upon observing varying degrees of growth inhibition to Pertuzumab and 
Trastuzumab in the three cell lines used, we next sought to determine whether these also 
achieve different degrees of RTK signaling inhibition. Specifically, we determined the 
levels of phosphorylated forms of HER2 Thr 877 (pHER2) and AKT Ser 473 (pAKT) 
following 96 h treatment with the HER2 targeting agents (Figure 5B).  
 
 At 96 h, there was more marked repression of pHER2 and pAKT in the PEO4 cell 
line than either OVCAR4 or SKOV3 cells, consistent with the observation of increased 
sensitivity of PEO4 to these inhibitors. Furthermore, treatment with a combination of the 
two agents usually achieved the highest inhibition of RTK signaling, again consistent 
with the highest growth inhibition seen in combination treatment in Figure 5A. Finally 
and again consistent with Figure 5A, OVCAR4 was found to have least inhibition of the 
phosphorylated substrates at all time points tested.  
 
NRF2 is a master regulator of the antioxidant response (AR) pathway [7], while KEAP1 
is its main regulator by functioning as an adaptor for ubiquitin ligase complex and 
promoting NRF2 degradation [54]. In the context of targeted immunotherapy, recent 
reports have suggested a role for NRF2 in determining overall treatment response [37, 55, 
56]. More specifically, several studies have either suggested direct cross talk of NRF2 
and RTK signaling [36], or modulation of NRF2 by the RTK substrates PI3K [57-59] and 
MAPK [42, 43]. Furthermore, both RTK mediated growth promoting pathways and 
NRF2 dependent antioxidant responses have been documented to lead to drug resistance 
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of cancer cells [60-64]. In light of these emerging roles of NRF2 in determining overall 
treatment responses, we next extended our investigation to study regulation of NRF2 and 
its degrader, KEAP1, in response to targeted therapies.  
 
 Treatment with HER2 inhibitors either alone or in combination on the contrary 
reduced NRF2 levels equally in our cell lines, consistent with previous studies [36].  The 
combination treatment caused a distinct repression in NRF2 levels in all three cell lines as 
compared to HRG treatment alone, whereas at the same time point, there was induction 
of KEAP1 in PEO4 and SKOV3 cell lines (Figure 5C).  Both NRF2 repression and 
KEAP1 induction were greater in PEO4 and SKOV3 cell lines than in OVCAR4, 
consistent with the cytotoxicity profiling (Figure 5A).  NRF2 is implicated in numerous 
contexts in causing drug resistance [62-65] and the observed repression of NRF2 
following combination treatment and greater repression in more sensitive cell lines is 
again consistent with a role for NRF2 in determining sensitivity to these targeted agents.  
 
To characterize these observations further in an in vivo context, we performed extensive 
bioinformatic analysis and data mining from in vivo SKOV3 xenograft model previously 
exposed to same HER2 target immunotherapies. We especially sought to determine the 
precise mechanism of combination-induced repression of NRF2 and its antioxidant 
function.  
 
Genetic reprogramming and NRF2 signaling following in vivo anti-HER2 
immunotherapy 
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We recently reported on some genetic cellular reprogramming events following 
HER2-targeted immunotherapy with Trastuzumab or Pertuzumab and their combination 
in an in vivo xenograft model of ovarian cancer [25, 32]. We re-examined the expression 
profile and microarray data previously reported [32, 48]. However, this time we digressed 
from global analysis of gene expression and focused on the NRF2 network using a 
knowledge-based approach that is largely informed by information reported in [50-54]. 
We analyzed gene expression data as before [28, 32] on the response of SKOV3 
xenograft tumors to Trastuzumab, Pertuzumab, and their combination treatments in the 
context of dynamic changes in the NRF2 network and signaling pathway. 
 
A total of 3599 transcripts of 2250 genes linked to the NRF2 network and 
function were identified in the array with 14, 15 and 24% either upregulated or down 
regulated significantly (p≤0.05) following Trastuzumab, Pertuzumab and combination of 
the HER2-targeted immunotherapies (Figure 6A; Table S1&S2). The volcano plots 
illustrated in Figure 6 B-D indicate transcripts of genes within the NRF2 network. 
Strikingly, we identified significant changes in expression within the genes of the NRF2 
network following immunotherapies relative to control values. Many of the differentially 
expressed genes in the NRF2 network due to combination treatment were already 
modulated by either Trastuzumab and/or Pertuzumab monotherapy. The Pertuzumab and 
combination treatments produced greater effects in gene expression changes in ascending 
order of magnitude relative to Trastuzumab, both in terms of significant (p≤0.05) down- 
and up-regulation of genes (Figure 6 E&F; Table S1&S2). Specifically some of these 
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transcripts were significantly down regulated (p≤0.05) following immunotherapy of 
which 87, 121, and 220 were due to Trastuzumab, Pertuzumab and combination of 
respectively. Furthermore, a total of 19, 31, and 56 genes and transcripts were commonly 
and significantly down regulated (p≤0.05) by Trastuzumab and Pertuzumab, by 
Pertuzumab and combination, and by Trastuzumab and combination, respectively. The 
significant down regulation (p≤0.05) of 26 genes was common to both single and 
combination therapies. Irrespective of either monotherapy or combination therapy, within 
the NRF2 network, the total up- and down-regulated genes, especially of the significant 
ones (p≤0.05) by each therapy were closely balanced and symmetrical (Figure 6 B-D, 
also see Table S2).  However, significantly greater volcanicity was observed with 
combination immunotherapy. Overall a total of 309, 354, and 540 genes were 
significantly affected (p≤0.05) by Trastuzumab, Pertuzumab, and their combination, 
which accordingly represent 1:1.2:1.8 fold differences in the number of affected genes 
within the NRF2 network following these immunotherapies, respectively. We could 
visualize these significant changes in the NRF2 network using heatmaps, however, due to 
the large number of the genes affected, we chose to present only the filtered heatmap 
showing genes that remained significant even at p=0.001 (Figure 6A). The higher number 
of modulated genes recorded with the combination therapy relative to the monotherapies 
is indicative of a more complex gene expression changes and cellular reprogramming 
events, which led to the observed greater cellular ROS production and compromise of 
cellular NRF2 levels and functions.  
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 More specifically, genes within the NRF2 network that were markedly expressed 
and down regulated following combination immunotherapy were detoxification and 
metabolism related AKR1B1, AKR1C1, ATP13A3, ATP1B1, ATP2A1, HMOX1, NQO1, 
FRMD6, GAPDH, GCLM, GCSH, GSTM4, H6PD, IDH1, PRDX1, SOAT1, SOD2, 
UGDH; DNA damage and repair related MLH3, MSH6, MYH4; cell signaling, 
proliferation, inflammation and immunity, and angiogenesis, related AKT3, AKTIP, 
CDH6, CXXC5, CXCL2, GSK3A, GSK3B, HACE1, ID1, KIT, KITLG, OSMR, PIK3AP1, 
PIK3IP1, PIK3R2, PIK3R5, RPS6KB1; EPHA2, FGF12, FGFBP1, FOS, FOSL2, FSTL1, 
IGF2BP3, JUNB, MAPK1, NGF, PDGFA, PDGFC, PDGFD, TGFA, TNFRSF1A, 
TAX1BP1, TUBB3, VEGFA, cell cycle regulation, cell survival and death related BAD, 
BARD1, BCL6, BCL2L15, BNIP1, CDK7, CDKN3, NAV2; as well as transcription and 
epigenetics control related AHR, ARNTL, BACH1, BACH2, BRCA1, BRCA2, ETS1, 
NFE2L2, NFKBIZ, RORA, RUNX2; BLM, HAT1, HMGB1, MED4, MET, METRN, 
METTL1, PRRX1, TES (Table S1&S2; Figure 6A). Likewise some genes within the 
NRF2 network that were markedly expressed and up regulated following combination 
immunotherapy were detoxification and metabolism related ABCB9, ABCC1, ABCC10, 
ACOX2, GPX2, GPX4, GSR, GSS, GSTA2, GSTM1, GSTM2, GSTM3, TALDO1, 
UGT1A6; cell signaling, proliferation, inflammation and immunity, and angiogenesis, 
related AKT1, CEBPA, DUSP5, DUSP5P, DUSP6, ERBB2, ERBB2IP, ERBB3, FOXA2, 
FOXJ2, FOXJ2, FOXO1, FOXO3, JUN, NFE2L1, PDGFB, RPS6KA2, RPS6KB2; cell 
cycle regulation, cell survival and death related CDKN1A, CDKN1B, CDKN2A, 
CDKN2B, CASP1, FRMD6, VAV3; as well as stability, transcription and epigenetics 
control related BACH1, BACH2, BTRC, KEAP1, MAFF, MAFG, MAFK, NOTCH1, 
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NOTCH3, PRRX2, NCOA6, NCOR1, RARA, RCOR3, RORA, RXRA, RXRB, RXRG, 
SYK, XBP1, HDAC1, HDAC3, HDAC5 (Table S1&S2; Figure 6A). Some similarly 
related gene expression changes were seen with single immunotherapy, Trastuzumab or 
Pertuzumab, but sometimes to a different magnitude and different direction. 
 
It is clear that Trastuzumab, Pertuzumab and combination have all produced 
significant induction of KEAP1 expression. Whilst Trastuzumab and Pertuzumab caused 
significant induction of NRF2 expression, their combination strikingly resulted in the 
profound and highly significant down regulation of NRF2 expression. These in vivo 
observations strongly supported our in vitro data (Fig 5C) regarding the status of NRF2 
and KEAP1 following immunotherapies. Further analyses and visualization of the in vivo 
gene expression data (Figure 7 and 8) confirmed our observed perturbations in the NRF2 
network and down regulation of some NRF2 target genes, especially genes associated 
with antioxidant responses and glutathione metabolism These give credence to our 
assertion of ROS production and compromise of NRF2 status and functions as the basis 
of action and effectiveness of the immunotherapies, especially with the combination of 
Trastuzumab and Pertuzumab. It is of interest to observe the up regulation of expression 
of HDACs and certain nuclear co-repressor genes, as well as the down regulation of HAT 
expression and its related functional homologues or orthologues such as DNA2, HES1, 
MED4, MET, METRN, METTL1, which point to transcriptional packaging and control. 
Consequently, we hypothesized that transcriptional silencing and epigenetics may 
contribute to the distinct mechanisms of inhibition of NRF2 function by combination 
immunotherapy. In an attempt to test this hypothesis, we used KEGG and knowledge-
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based approach to examine the in vivo gene expression data with particular attention to 
transcription and epigenetics pathways. The data obtained (Figure 8) supported this 
hypothesis, which we later confirmed using our in vitro cell models (Figs. 9 - 11). Overall 
there is agreement between the in vitro and the in vivo data. 
 
Combination treatment with Pertuzumab and Trastuzumab causes transcriptional 
repression of NRF2 leading to downregulation of expression of genes under its 
regulation   
 
In order to verify the in vivo data of microarray and confirm transcriptional 
inhibition of NRF2 in our own cell line models, we adopted two approaches. Firstly, we 
performed quantitative RT-PCR (qRT-PCR) on cDNAs obtained from PEO4, OVCAR4 
and SKOV3 previously exposed to combination treatment of Pertuzumab and 
Trastuzumab for 96 h. In this experiment, we firstly quantitatively determined basal 
expression levels of NRF2 and its substrates HO-1 and GCLM through qRT-PCR (Figure 
9A). Consistent with previous reports, we found significantly higher basal levels of NRF2 
[31] as well as HO-1 and GCLM levels in PEO4 than OVCAR4 and SKOV3, with 
OVCAR4 having the least expression levels. More importantly, following 96 h of 
treatment with combination of Pertuzumab and Trastuzumab, there was significant 
downregulation of NRF2 expression in all the three cell lines tested. Furthermore, HO-1 
and GCLM expression were reduced following the same treatments (Figure 9B). This 
demonstrated and confirmed that targeted therapy cause transcriptional repression of 
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NRF2 leading to downregulation in expression of its transcriptional substrates and as 
such confirmed the in vivo microarray data.  
 
In the second and related strategy, we cloned the 1.5kb promoter region of NRF2 
gene into a luciferase reporter vector to generate a luciferase based reporter assay for 
NRF2 transcription (called prNRF2). This reporter was used to directly report any 
transcriptional perturbation of NRF2. We transfected prNRF2 into our ovarian cancer cell 
lines, repeated the immunotherapeutic combination treatment for 96 h and assayed cells 
for luciferase activity (Figure 9C). We found that indeed combination treatment 
significantly reduced luciferase signal, demonstrating transcriptional inhibition of NRF2 
expression in both PEO4 and SKOV3 cell lines. In this transient transfection strategy, by 
96 h, we could not obtain any detectable expression of our vectors in OVCAR4 (data not 
shown). These experiments clearly demonstrated transcriptional inhibition of NRF2 and 
explain the repression of NRF2 protein seen before (Figure 5C).  
 
HER2 targeting immunotherapeutic agents cause upregulation of HDAC1 and 
repression of phospho HDAC levels demonstrating HDAC activation.  
 
A noticeable feature in our in vivo microarray data analysis was the finding that 
several histone deacetylases (HDACs) levels were upregulated (Figure 7). Upregulation 
and activation of HDAC1 would lead to diminished acetylation, increased methylation 
and subsequent repression of gene expression [66, 67]. We next sought to determine 
whether upregulated HDAC1 could be reproduced in our cell lines following 
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combination treatment in vitro, which could further serve to explain the transcriptional 
downregulation of NRF2 expression during such treatments. Firstly, we immunoblotted 
for total HDAC1 in our three cell lines and saw induction of HDAC1 only in combination 
treatment, albeit to different levels in each cell line (Figure 10A). Furthermore, we 
fluorescently immunostained total HDAC1 and confirmed nuclear upregulation following 
combination treatment (Figure 10B).  We next examined phosphorylated levels of 
HDAC4 (Figure 5 &7). Phosphorylation of HDAC was previously shown to repress its 
activity by nuclear export [68, 69]. We found a clear repression of phospho-HDAC 
following combination treatment for 96 h in PEO4 and OVCAR4 cell line. However, in 
SKOV3, we could not see such repression (Figure 10C).  
 
Inhibition of HDAC and DNA methyl transferases induce NRF2, HO-1 and 
transcriptional antioxidant response, and disrupt immunotherapy dependent repression 
of NRF2 
 
While the diminished levels of NRF2 protein seen earlier could be partly 
explained by induction of KEAP1 during some treatments, the same does not explain its 
transcriptional repression. Upregulation of HDAC1 as seen in Figure 10 on the other 
hand warrants itself for further study, as this could be a potential mechanism of 
transcriptional repression of NRF2, especially upon the finding of HDAC1 induction 
following combination treatment.  
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For these reasons, we next tested this assumption by repeating exposure of our 
cells to the combination of Pertuzumab and Trastuzumab, but also treating cells with 
combination of inhibitors of HDAC1, Trichostatin (TSA) or that of DNA methylation, 
namely 5-azacytidine (5-Aza) [70, 71], collectively called T/A. Both these inhibitors are 
expected to relief transcriptional inhibition of genes that are under epigenetic regulation 
and silenced by DNA methylation dependent mechanisms. We found that not only did 
T/A lead to NRF2 induction, suggesting relief of methylation dependent suppression of 
its gene expression, but more importantly, it also disrupted the inhibitory action of 96 h 
of HER2 inhibitors treatments (Figure 11A). We could also show such T/A dependent 
induction of both NRF2 and its downstream transcriptional target, HO-1 at single cell 
level by performing immunostaining (Figure 11B). This important finding firstly 
demonstrated that NRF2 gene expression could be subjected to epigenetic regulation 
involving DNA methylation and/or acetylation; secondly, that the inhibition of NRF2 
following exposure to HER2 targeting drugs involves the above mechanism; thirdly that 
as such, this could be disrupted by using specific inhibitors also leading to induction of 
NRF2 substrates. We next made use of AREc32 cell line, the stable clone of antioxidant 
response reporter to further study the consequences of HDAC1 and DNA methylation 
inhibition on NRF2 dependent antioxidant response pathway. In this strategy, we used 
TSA and 5-Aza either alone or with classical activators of NRF2 to see whether that 
would lead to further antioxidant activation. While the classical NRF2 activator, tert-
butylhydroquinone (tBHQ) and sulforophane induced ARE signal by 13 and 2.5 fold 
respectively, TSA alone led to almost 35-fold induction (Figure 11C). Furthermore, TSA 
could further enhance ARE signal in tBHQ treated cells to more than 70 fold. These 
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findings further validated our earlier assumption of the involvement of epigenetic 
mechanisms in regulating NRF2 and hence its downstream antioxidant pathway.  
 
To further confirm the transcriptional mechanism of NRF2 regulation following 
T/A treatments, we used prNRF2, our cloned NRF2 luciferase based promoter assay as its 
transcriptional reporter. We found that while combination treatment of Pertuzumab and 
Trastuzumab repressed NRF2 transcription, cotreatment with T/A disrupted this 
repression in both PEO4 and SKOV3 cell line with the latter showing a more pronounced 
induction of NRF2 transcription following T/A cotreatment (Figure 11D).  
 
Altogether, findings in this set of experiments demonstrate the involvement of 
transcriptional and epigenetic mechanisms of NRF2 regulation with its effects seen both 
at the transcriptional, single cell and overall protein levels.  
 
Anti HER2 targeted therapy causes NRF2 promoter methylation explaining its 
transcriptional repression following HER2 inhibition.  
 
In order to more directly determine the epigenetic basis of NRF2 regulation 
following combination of HER2 targeting drugs, we performed epigenetic study of NRF2 
promoter involving methylation profiling. This was also done to explain the 
transcriptional and protein induction of NRF2 followed by activation of its antioxidant 
function upon inhibition of HDAC and DNA methylation. To do this, we first performed 
in silico analysis of the NRF2 promoter to identify CpG islands (Figure S1A). This was 
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done using the CpG analysis program Methprimer (http://www.urogene.org/methprimer/ 
). This analysis identified a CpG island containing 18 CpG dinucleotides (Fig 12C and 
Figure S3A). We next designed primers specific for amplification of bisulfite converted 
DNA but not unconverted DNA, exposed all three cell line models of this study to 96 h of 
Pertuzumab and Trastuzumab combination treatment, isolated total genomic DNA from 
exposed cells and performed its bisulfite conversion. Such conversion converted all the 
non-methylated cytosine nucleotides in the DNA to Thymine, whereas the methylated 
cytosines being resistant to such conversion remained intact. Using the designed bisulfite 
conversion specific primers flanking the predicted CpG island, we set up PCR, amplified 
this region, purified and sequenced it (Figure S3). Careful analysis of the sequencing 
results revealed striking differences in the sequences between untreated and treated cell 
lines (Table 3). We found that only one CpG dinucleotide among the 18 predicted was 
methylated in the PEO4 cell line in the untreated state (CpG dinucleotide at position 206, 
Figure 11C). However, following treatments, we found a total of six CpG dinucleotides 
retained following conversion, suggesting their methylation (CpG dinucleotides at 
positions 43, 79, 159, 163, 184 and 206, Figure 11C). OVCAR4, which showed the least 
inhibition of NRF2 protein following drug treatment also exhibited limited CpG 
methylation with only three CpG dinucleotides showing methylation (position 138, 184 
and 245). A surprising finding was with SKOV3, which only exhibited a single 
conservation of the CpG dinucleotide, suggesting a single methylated cytosine at position 
157 (Figure 12C). The disparity between a very pronounced NRF2 protein inhibition in 
SKOV3 (Figure 5C) while still very limited methylation profile could be explained by the 
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fact that KEAP1 induction during the same treatments was the highest in this cell line 
potentially accounting for this as a contributing factor in NRF2 repression.  
 
This is the first report of NRF2 promoter methylation profiling following HER2 
targeted immunotherapy. This novel finding demonstrated for the first time that the 
human NRF2 promoter in three ovarian cancer cell lines exhibited methylation following 
combination treatment and hence identifies a novel mechanism of transcriptional 
repression of NRF2.  
 
DISCUSSION  
 
The introduction of monoclonal antibody based targeted anticancer 
immunotherapy in the form of HER2 targeting Trastuzumab (Herceptin) and Pertuzumab 
has opened a new chapter in cancer immunotherapeutics. It has significantly improved 
our understanding of the biology of HER2-related cancers and the emergence of novel 
anti-HER2 drugs for the treatment of cancers. While several mechanisms, including 
inhibition of proliferation and angiogenesis, DNA repair and extracellular domain 
cleavage for recruiting host immune natural killer (NK) cells and triggering of an 
antibody-dependent cell-mediated cytotoxicity (ADCC) process [75] have been identified 
for Trastuzumab, the mechanism of action of Pertuzumab has appeared limited to 
primarily inhibiting signal transduction by blocking the function of HER2. Several in 
vitro and in vivo studies have clearly elucidated this mechanism of action by Pertuzumab 
[76-79]. Although these therapies work by different mechanisms, it appears that to exert 
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an antitumor effect, they should for example inhibit phosphorylation of HER3 and 
antagonise the PI3K/AKT pathway [25, 28, 29]. Detailed experimental and clinical 
studies have shown the complimentary and enhanced efficacy and safe tolerability of 
HER2 targeting and blockade by the novel combination of Trastuzumab with Pertuzumab 
[32, 80-84]. However, treatment outcomes with single agent or combination of agents 
remain fairly unpredictable, tumour type specific and tumour biology dependent, 
especially the expression levels of cell surface receptors, their dimerization preferences, 
recycling kinetics and ligand abundance [25, 33-35, 85]. Also the molecular mechanisms 
responsible for susceptibility and de novo and/or acquired resistance to these HER2 
targeted immunotherapeutic agents are poorly understood. In this study we aimed to 
identify and characterise novel signalling pathways that might explain the efficacy of 
HER2-targeted immunotherapies that are critical to avoid or to overcome resistance. 
In the current study, we sought to determine the mechanism of action of targeted 
immunotherapeutic agents and in particular to understand the enhanced cytotoxic 
response triggered uniquely by combination of immunotherapeutics rather than individual 
agents. We determined the degree of sensitivity of ovarian cancer cells derived from 
different origins to the HER2 targeting antibodies, Pertuzumab and Trastuzumab, either 
employed alone or in combination. These ovarian cancer cell lines are of low 
(OVCAR4), moderate (PEO4), and high (SKOV3) HER2 expression status [34], in 
addition to having variable expression levels of HER3, the key dimerization partner of 
HER2 in the order PEO4>OVCAR4>SKOV3 [34]., We found that at least part of 
mechanism of action of the HER2 targeted immunotherapeutic agents involved 
generation of ROS, which contributed to the killing effects and cancer growth retardation. 
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This is consistent with the conventional adage that depletion of GSH can cause oxidative 
stress and sensitise tumours to the killing effects of the therapeutic agents. These 
observations were further reinforced by the use of NAC to attenuate ROS and desensitise, 
or of RA to elevate ROS, and augment the cytotoxicity of Trastuzumab and Pertuzumab.  
The cell lines exhibited complex and different degrees of cytotoxicity to 
Pertuzumab and Trastuzumab alone or their combination. However, the combination 
treatments produced the greatest cytotoxicity and killing effect, as well as the highest 
inhibition of RTK signalling, consistent with previous observations [25, 32, 33]. Since we 
have recently characterised these cell lines as having different levels of NRF2, 
KEAP1,hierarchical addiction to ROS and its potential for manipulation, intricate with 
their proliferative capacity [10,11], we postulated any or all of these to be possibilities for 
the observed differential response to the different immunotherapies, especially the 
combination therapy. The rationale for this postulate was the fact that RTK and AR 
pathways share common substrates, both pathways are cytoprotective and pro-survival in 
nature and both these have been implicated in drug resistance. Additionally, recent 
studies have explored and identified co-modulatory and co-regulatory roles of the two 
pathways [36-39].  
 
Interestingly, combination of the targeted immunotherapeutic agents (Pertuzumab 
and Trastuzumab) caused down regulation of NRF2, induction of KEAP1, and depletion 
of glutathione, features that were ascribable to inhibition of the NRF2 dependent 
antioxidant transcriptional program. These demonstrated that HER2 targeting monoclonal 
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antibodies repress the NRF2 dependent antioxidant pathway, which may contribute to the 
enhanced cytotoxicity for the combination of Pertuzumab and Trastuzumab.  
 
Next, we sought evidence that the mechanism of action and effectiveness of 
HER2 targeted immunotherapies, in particular the combination of Trastuzumab and 
Pertuzumab, in vivo, is characterised by inhibition of NRF2 function. We did this by 
performing a series of in vitro experimentation, as well as bioinformatic analysis of 
microarray data from the in vivo SKOV3 xenograft model of HER2 targeting 
immunotherapies [32] as before [25]. In our analysis of gene expression we focused on 
the NRF2 network using a knowledge-based approach that was informed by previous 
reports [50-54]. Firstly, we demonstrated that the suppressive effects of combination 
therapy on the AR pathway seen in vitro (Figure 1-2) were reproduced in vivo (Figure 6-
8). Significant changes in the gene expression of NRF2 and the NRF2 network signalling 
were observed following treatment with anti-HER2 immunotherapies in the SKOV3 
xenograft. The most dynamic effects and changes were seen with the combination 
therapy. Up regulation of some of the genes within the NRF2 network can be explained 
by the takeover of transcriptional control of such genes by other significantly induced 
transcription factors like the FOXO family and NFE2L1 (NRF1). Thus the in vivo model 
supported and confirmed the results of our in vitro model, which showed that the 
effectiveness of HER2-target immunotherapy is greatly and significantly informed by 
repression of NRF2 and its antioxidant function. A number of classical NRF2-dependent 
genes like AKR1C1, ATP1B1, BRCA1, BRCA2, GAPDH, GCLM, GCSH, GSTM4, H6PD, 
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HMOX1, IDH1, NQO1, PRDX1, SOAT1, SOD2, UGDH TUBB3, and VEGFA were 
suppressed, especially with combination therapy.  
 
Several possible mechanisms of NRF2 inhibition seen in vitro and in vivo could 
be identified and explained from the microarray analyses. First, the classical NRF2 and 
KEAP1 relationship, levels and dynamics appeared to be in place following the HER2 
target immunotherapies in vivo as observed with the in vitro model. The expression of 
NRF2 significantly decreased following combination treatment. This supports the notion 
that NRF2 opposes the action and effectiveness of Trastuzumab and Pertuzumab, perhaps 
by promoting the sequestration of the ROS generated to kill cells following immunogenic 
drugs administration. Further, this notion is strengthened and supported by the 
observation that the expression of KEAP1 was significantly induced following both 
single and combination treatments with least induction observed under combination 
treatments. However, the ratio of NRF2/KEAP1 expression was higher under single agent 
than with combination treatments, suggesting greater degradation and inhibition of NRF2 
function [7, 8] with combination than with single agents.  
  
The mechanisms by which retinoic acid (RA) inhibits NRF2 and its function are 
known [62, 86] and have been the basis for our use of RA to modulate cellular NRF2 
status, ARE-dependent transcriptional program and to implicate NRF2 in regulating 
cellular susceptibility to HER2 targeted immunotherapies. Interestingly, we found 
increased expression of RXR and RARA genes following Trastuzumab, Pertuzumab, and 
their combination treatment of the SKOV3 xenograft tumours. This suggested that these 
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mechanisms may play a part in vivo to inhibit NRF2 function and thus influence the 
effectiveness of the HER2 target immunotherapies. Also GSK3 expression appeared 
stable and the expression of FYN kinase was induced, by all the immunotherapies against 
the SKOV3 xenograft tumours, especially with combination therapy where the 
expression of β-TrCP was induced, which highlights another possible mechanism of 
controlling NRF2 levels and functions [87-89]. Further, the down and up regulation of 
BACH1 and BACH2 expression following single agent and combination therapy, 
respectively, could help explain the greater loss of NRF2 function in the combination 
therapy, since BACH is a negative regulator of ARE-NRF2-dependent transcription of 
genes [90-92]. Moreover, there was up regulation of expression of MAF gene family 
(MAFF, MAFG, MAFK), especially following combination therapy, an observation that 
agrees with the notion of the negative regulation of ARE-NRF2 dependent transcriptional 
program [93, 94].  
   
Further analyses and visualisation of the in vivo gene expression data confirmed 
perturbations in the NRF2 network and down regulation of some NRF2 target genes, 
especially genes associated with antioxidant responses (AKR1B1, AKR1C1, HMOX1, 
NQO1, FRMD6, GAPDH, IDH1, PRDX1, SOAT1, SOD2) and glutathione metabolism 
(ATP1B1, ATP2A1, GCLM, GCSH, GSTM4, H6PD). These supported the role of ROS 
production and the undermining of NRF2 status and functions as the bases of action and 
effectiveness of the immunotherapies, especially with the combination of Trastuzumab 
and Pertuzumab. It is pertinent to describe the up regulation of expression of HDACs 
(HDAC1, HDAC3, HDAC5, SIRT7), histone methyl transferases with CpG binding 
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protein (CXXC1) and certain nuclear co-repressor genes (NCOA6, NCOR1, PRC1, 
RCOR3), as well as the down regulation of expression HAT and its related functional 
homologues or orthologues like DNA2, HES1, MED4, MET, METRN, METTL1. These 
observations highlighted genetic and transcriptional packaging, suturing and control, 
which consequently led us to hypothesise that transcriptional silencing and epigenetics, as 
shown before [95, 96] may contribute to the distinct mechanisms of inhibition of NRF2 
function by combination immunotherapy. These data and those from the NRF2 gene 
promoter methylation, transcriptional assays and HDACs dynamics using our in vitro cell 
models supported the hypothesis. Overall there is agreement between the in vitro and the 
in vivo data which together illustrate the important role of NRF2 in influencing outcomes 
to targeted therapies involving HER2 receptor inhibition. Moreover, our recent work on 
the regulation of HER2 and HER3 by NRF2 to oppose HER2 targeted immunotherapy 
[45], gives further support and credence to this assertion. The study has also opened up a 
new potential avenue of improving the effectiveness of Trastuzumab (Herceptin), which 
currently benefits less than 30% of breast cancer bearing patients and as Trastuzumab-
associated chemotherapy can modulate the pro-inflammatory markers of HER2-positive 
breast cancer patients [97].  
 
CONCLUSION 
 
We have elucidated a novel mechanism of action for the combination of HER2 
target anticancer immunotherapeutic agents. We demonstrate that combination treatment 
with HER2 targeting monoclonal antibodies Pertuzumab and Trastuzumab cause greater 
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inhibition of NRF2 function and subsequent greater repression of NRF2 dependent 
antioxidant responses in human ovarian cancer cell lines. The degree of repression of 
NRF2 determines the overall sensitivity of cancer cells towards the HER2 targeted 
therapies, an axis that could be modulated to further sensitise otherwise resistant ovarian 
cancer cells. Furthermore, we present evidence that methylation leading to transcriptional 
repression and gene silencing at the NRF2 promoter occurs following combination of 
Pertuzumab and Trastuzumab treatments. Therefore the greater effectiveness and 
enhanced cytotoxic action of the combination of the HER2 targeted immunotherapeutic 
agents may be at least partially  explained by their unique ability to cause transcriptional 
inhibition of NRF2 and greater repression of its antioxidant function in low, moderate 
and high HER2 expressing ovarian cancer cell lines. This study expands the role of NRF2 
as a key element in driving drug resistance and opens up a novel strategy of sensitising 
cancer cells to HER2 targeted therapy, as well as overcoming the resistance of cancer 
cells to such immunotherapeutics. 
 
MATERIALS AND METHODS 
 
Cell lines, culture conditions and treatments 
 
Human ovarian cancer cell lines PEO4, OVCAR4 and SKOV3 were maintained 
in RPMI 1640 media (Gibco® Invitrogen) supplemented with 10% foetal bovine serum 
(FBS), 2 mM glutamine, 1 mM sodium pyruvate, 100 μg/ml streptomycin and 100 U/ml 
penicillin in an atmosphere of 5% CO2 and incubated at 37oC. Before experimental 
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treatments, cells were grown for 24 h in RPMI 1640 media prepared as above but 
replacing FBS with 5% double charcoal stripped FBS (Fisher). Heregulin-β1 (HRG, 
Sigma) was used by preparing 1 µM stock solution made with 5% trehalose, 10% FBS in 
PBS and diluted to a final concentration of 1nM with media during treatments. 
Monoclonal antibodies targeting HER2 receptor, Pertuzumab and Trastuzumab or their 
combinations were used by directly diluting the drugs in media to a final concentration of 
20 µg/mL. For Retinoic acid (RA) treatments, a stock solution of 40 mM was made in 
100% ethanol in amber Eppendorf tubes pre-aired with nitrogen gas. Once the stock 
solution was made, it was bubbled again with nitrogen gas and closed, stored at -80OC 
and protected from light until further use. A final concentration of 2.5 µM was used for 
treatments. For reducing conditions, 100 mM N-Acetyl Cysteine (NAC, Sigma-Aldrich) 
was prepared in deionised water and diluted to a final concentration of 10 mM with 
media during treatments. For ROS detection, 2′,7′-Dichlorofluorescin diacetate (DCFDA, 
Sigma) solution was prepared with Dimethylsulfoxide in amber tubes to a concentration 
of 50 mM and stored at -20oC in dark until used. For cytotoxicity assay, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) was used by making a 
stock solution of 5 mg/mL in PBS and filter sterilising it. The solution was stored at 4oC 
in the dark until used. To inhibit DNA methylation, 5-azacytidine and HDAC inhibitor 
Trichostatin A (collectively referred to as T/A) were used at final concentration of 2 µM 
and 200 nM respectively. Mock treatments with DMSO were performed in parallel.  
 
Reactive Oxygen Species (ROS) detection 
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The ROS detection assay was performed by using 2′,7′-Dichlorofluorescin 
diacetate (DCFDA) staining (Sigma). Briefly, cells were seeded in triplicate at a density 
of 5×103 cells/well in opaque flat bottom 96-well tissue culture plates in 100μl media 
without phenol red and allowed to grow for 24 h before being exposed to different 
treatments. Following required treatments, a 50mM stock solution of DCFDA was added 
to each well containing 100 µL pre-existing media to achieve a final concentration of 25 
µM and incubated for 45 min at 37oC. Fluorescence signal intensities indicating ROS 
levels were recorded by taking readings using 96-well fluorescent multi plate reader 
(MODULUSTM, Promega) using excitation and emission spectra of 485/535 nm. To 
normalise the fluorescence signal, cells in the same wells were subsequently stained with 
coomassie brilliant blue stain (Sigma-Aldrich) for 1 h, washed with distilled water and 
10% SDS solution added to release the absorbed dye for 10 min while shaking. The 
absorbance values at 595 nm were then recorded using multiplate absorbance reader 
(MODULUSTM, Promega) and data used to normalise the fluorescence values.  
 
Protein extraction and immunoblotting 
 
For immunoblotting, cells were seeded in 60mm tissue culture plates and grown 
until 70% confluent and exposed to required treatments. At protein harvest, cells were 
trypsinized (Gibco® Invitrogen), washed with PBS, and harvested to obtain protein 
lysates using RIPA buffer (Pierce Biotech) supplemented with protease and phosphatase 
inhibitor cocktail (Pierce Biotech). The lysates were subjected to sonication of 2 cycles 
for 10 s at 50% pulse. The final mixture was shaken gently on ice for 15 min and the 
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protein supernatant was obtained following centrifugation of the lysates at 14000 x g for 
15 min. Proteins obtained were quantified by Bradford assay (Sigma-Aldrich) using BSA 
as a standard and sample buffer (Nupage LDS, Invitrogen) was added to protein lysates, 
heated at 70°C for 20 min and stored at -20°C until further use. On the day of 
immunoblotting, lysates were loaded into wells of 4-12% gradient SDS-polyacrylamide 
gels (Nupage® Bis-Tris gels, Life Technologies) and subjected to electrophoresis at 
200V for 1-2 h.  Following this, proteins were transferred to polyvinylidene difluoride 
membranes (GE Amersham) using the XCell SureLock Mini-Cell system (Invitrogen) at 
50V for 90 min and processed using a commercially available kit (WesternBreeze™ 
Chromogenic Immunodetection Kit, Invitrogen). Non-specific reactivity was blocked by 
incubation with the blocking reagent supplied in the kit. Membranes were further treated 
by incubating with primary antibodies (Table 1) for 2 h at room temperature or overnight 
at 4oC, followed by incubation for 30 min at room temperature with appropriate 
secondary anti rabbit antibody supplied in the kit. Bands were visualized with the 
BCIP/NBT based chromogenic substrate. For loading control, either immunoblotting of 
the same lysates was performed using β-Actin antibody (Abcam Bioscience, UK) or the 
PVDF membranes with transferred proteins visualized using Ponceau stain (Sigma).   
 
Cloning and expression vector. 
 
The 1.5kb proximal promoter region of NRF2 upstream of its translational start 
site was cloned into a luciferase reporter vector (Promega) and used to study the 
transcriptional regulation of NRF2. Table 2 lists the primers for the amplification of the 
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NRF2 promoter. Total genomic DNA was isolated from human cells using DNeasy 
Blood and tissue kit (Qiagen) and quantified using AstraGene microvolume 
spectrophotometer (AstraNet). 100ng of the genomic DNA was used to amplify the 
promoter sequences with MyFi mix (Bioline), using primers that incorporated XhoI and 
NcoI restriction endonuclease sites 5’ and 3’ ends of the amplified NRF2 promoter 
respectively. PCR conditions for promoter amplification were initial denaturation of 95 o 
C for 7 min followed by 35 cycles of 95 o C for 30 s for denaturation, a gradient annealing 
temperature of 50-60o C for 30 s and 72 o C for 90 s for extension and a final extension for 
10 min at 72 oC. The PCR products were subjected to electrophoresis and extracted from 
agarose gel (Qiagen), digested using XhoI and NcoI restriction enzymes (Promega) and 
ligated into pGL3 basic luciferase vector (Promega) to create the NRF2 promoter 
construct (prNRF2) driving the expression of Luciferase gene for utilization in a Dual 
luciferase reporter assay (Promega). The integrity of cloned sequences was determined by 
commercial sequencing service (www.dnaseq.ac.uk). The NRF2 promoter construct was 
transfected into relevant cell lines using Lipofectamine® 3000 (Life Technologies) as a 
transfection reagent.  
 
Luciferase reporter assay 
 
For the analysis of promoter activities and transcriptional regulation of NRF2, the 
1.5 kb promoter region of NRF2 gene cloned in pGL3 basic vector (Promega) was 
transfected into relevant cell lines. Briefly, cells were seeded in triplicates in 24-well 
plates at a density of 2×105 cells per well and allowed to attach for 24 h. Following this, 
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cells were either transfected with 1 µg of empty pGL3 basic vector (Promega) or PGL3 
basic vector with cloned fragments of NRF2 promoter driving the expression of luciferase 
gene, using transfection reagent Lipofectamine 3000® according to manufacturer’s 
instructions (Life Technologies). Co-transfection was also performed with 0.2 µg of pRL-
CMV vector (Promega) expressing renilla luciferase to provide an internal control of 
transfection. Following this, cells were allowed to grow for 24 h, subjected to desired 
treatments, lysed and protein lysates transferred to opaque white bottom 96-well plates. 
The dual luciferase activity of fire fly luciferase (from cloned promoters) and Renilla 
(internal control) in the harvested lysates was measured sequentially by following 
manufacturer’s instructions (Promega) and taking luminescence readings in a 
luminometer (MODULUSTM, Promega). To determine the NRF2 dependent 
transcriptional antioxidant response following different treatments, stable clones of 
MCF7 cells carrying pGL3 vector with a cloned 8 copies of Cis-Antioxidant Response 
Elements (ARE) were used as stable luciferase reporter cells (AREc32) to report NRF2 
dependent transcription [98]. Briefly, AREc32 cells were seeded in quadruplicate in 24-
well plates at a density of 0.5×105 cells per well and allowed to attach for 24 h. Next day, 
cells were washed with pre-warmed PBS, treated as required and further allowed to 
incubate for the desired time period. Towards the end of treatments, 250 µL of the 
reconstituted luciferase reagent (Bright GloTM Luciferase, Promega) was added in each 
well containing 250 µL of pre-existing media and the plate incubated at 37oC for 10 min. 
100 µL of the cell lysate was transferred to opaque white bottom 96-well plate for 
luminescence detection in a luminometer (MODULUSTM, Promega) while 50µL was 
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subjected to Bradford assay to estimate protein content for the normalization of 
luminescence signal.  
 
Cytotoxicity assay 
 
Cytotoxicity assays were performed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT). Briefly, cells were seeded in triplicates at a density 
of 0.5×104 cells in 96-well plate and allowed to attach for 24 h. Following this, old media 
was removed and 80 µL of media containing relevant drugs was added and the plate 
incubated for the required period of time. On the day of assay, 20 µL of the 5mg/mL 
MTT stock was added to each well and the plate further incubated for 4 h. Following this, 
the old media with MTT was removed, cells gently washed with pre-warmed PBS and 
100 µL of DMSO added to solubilize the internalized MTT by shaking the plate over an 
orbital shaker for 15 min. Absorbance of the released dye was measured and recorded 
using multiplate reader (MODULUSTM, Promega) at 540 nm.  
 
Immunocytochemistry/Immunolabelling 
 
For immunocytochemistry, exponentially growing cells were seeded at a density 
of 5 ×104 cells in media onto poly-L lysine (Sigma-Aldrich) coated cover slips placed in 
a 12-well tissue culture plates and allowed to attach for 24 h. Following relevant 
treatments, cells were washed three times with ice cold PBS and fixed in 3.5% 
paraformaldehyde in standard PBS at room temperature for 30 min. Next, cells were 
40 
 
gently washed twice with 1 ml of PBS, permeabilized with 0.3% triton X-100 in PBS for 
10min, and following three washes with PBS, blocked with a solution containing 1% goat 
serum, 1% bovine serum albumin and 0.05% Triton X-100 in PBS for 30 min. Cells were 
then incubated with relevant primary antibody (Table 1) diluted in blocking solution for 1 
h, washed three times with 0.1% Triton X-100/PBS for 5 min, and then incubated with 
Alexa Fluor 488 or 568- conjugated goat anti-rabbit secondary antibody (Table 1) for 30 
min. After subsequent three washes with the 0.1% Triton X-100 in PBS for 5 min, cover 
slips with cells were mounted on slide using 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI)-containing mounting reagent (Life technologies) and imaged 
under relevant filters with a Leica DMiRe2 electronic microscope.  
 
Imaging and analysis 
 
Quantitative analysis of raw immunoblots was performed by capturing the images 
in high resolution TIFF format files using a charge-coupled-device camera (AxioCam 
MRc, Carl Zeiss) and subjected to Gelpro analysis software, version 3.1 (Gelpro Media 
Cybernetics) for integrated optimal densitometry. Fluorescence images of 
immunocytochemistry were collected under relevant excitation and emission filters 
depending on the fluorotype under Leica DMiRe2 electronic microscope equipped with 
iXonEM +897 EMCCD camera (ANDOR Technologies Ltd). Images were analyzed 
using multidimensional microscopy software Andor Module iQ Core. Colocalization 
assay was performed and determined with software integral features supplied by Andor 
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IQ core software. Data were generally expressed as mean ± S.D. for individual sets of 
experiments. 
 
Bisulfite sequencing and promoter methylation analysis 
 
Bisulfite conversion of the genomic DNA extracted from ovarian cell lines was 
performed using EpiTect Fast LyseAll Bisulfite Kit (Qiagen) using manufacturer’s 
instructions. Briefly, ovarian cancer cells were seeded in 60 mm plates and allowed to 
attach for 24 h. Following this, cells were exposed to different treatments for required 
period of time, trypsinized, centrifuged and pellets suspended in 150 µL cold PBS. From 
this mixture, 10 µL was used for DNA extraction using the lysis buffer supplied in the 
kit, bisulfite converted following manufacturer’s instructions and the final elute 
quantified using AstraGene microvolume spectrophotometer (AstraNet) to obtain a 
concentration of 20 ng/µL genomic DNA. Next, 100 ng of the extracted DNA was 
subjected to PCR amplification (Myfi mix, Bioline), using bisulfite specific primers 
(Table 2) applying PCR conditions of 95oC for 7 min for initial denaturation followed by 
30 cycles of 95oC for 30 s denaturation, 50 oC for 30 s for annealing and 72 oC for 90 s for 
extension and a final extension at 72oC for 10 min. Unconverted DNA extracted from 
same cells were used as negative controls. The products were run on 1.5% agarose gel 
and analyzed for integrity and size (supplementary Figure 5) and sent to a commercial 
sequencing service (www.dnaseq.co.uk ) to identity the sequences. For in silico analysis 
of promoter methylation and prediction of CpG islands in NRF2 promoter, the 
Methprimer (www.urogene.org ) online resource was used. Firstly, a 1.5 kb human NRF2 
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promoter sequence was retrieved from Ensembl genome browser (Ensembl.org) and 
provided as input to the Methprimer software. Following further analysis, a 270 bp region 
with 18 predicted potential methylated sites was identified. The primers, which were 
specific for Bisulfite converted DNA, were selected and ordered (Table 2) and used to 
amplify 270 bp region of genomic DNA isolated from PEO4, OVCAR4 and SKOV3 
cells following relevant treatments.  
 
Quantitative Real-Time PCR (qRT PCR) 
 
Quantitative real-time PCR (qRT PCR) was performed using Taqman® Universal 
master mix (Life technologies). The probes and primers for human NRF2 
(Hs00975961_g1), HO-1 (Hs00157965_m1) and 18s RNA (Hs03928992_g1) were 
obtained from life technologies and previously validated by the manufacturers. For 
GCLM, custom-made primers were used with the sequence and probe listed in Table 2. 
Real time PCR, analysis and processing of obtained data were performed by Stratagene 
Mx 3000P PCR amplification machine and built-in software (Agilent Technologies). 
Briefly, PEO4, OVCAR4 and SKOV3 cell lines were seeded in 60 mm plates and grown 
until 70% confluent. Following this, cells were washed once with warm PBS and new 
media with required treatments added for the desired period of time. Total RNA was 
extracted from treated cells using Trisure (Bioline) and its integrity and quality was 
determined by agarose gel electrophoresis and quantified using AstraGene microvolume 
spectrophotometer (AstraNet). 500 ng RNA was next used to convert to cDNA with the 
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Affinity Script cDNA synthesis kit (Agilent Technologies). The cDNA was subjected to 
qRT PCR using relevant probes and primers as listed in Table 2.  
 
Statistical analysis 
 
All statistical analysis were performed using statistical software SPSS (IBM, 
version 22). Test for normality of data was determined by Shapiro-Wilk and Kolmogorov 
and Smirnov tests. The significance (p value) of differences of pooled results was 
determined by either independent t tests or One WAY ANOVA followed by post hoc 
Tukey’s tests. Significance was defined as * = p< 0.05, ** = p<0.01, *** = p<0.001.  
 
Glutathione assay 
 
Total cellular Glutathione (GSH) levels were determined by using the GSH assay 
kit (Sigma) according to the protocols described by Tietze F, 1969 [99]. 
 
Bioinformatics methods and in vivo analysis 
 
Microarray data on gene expression (GSE31432; NCBI Gene Expression 
Omnibus https://www.ncbi.nlm.nih.gov/geo) following Trastuzumab (20 mg/kg), 
Pertuzumab (20 mg/kg) and the combination treatment from SKOV3 tumor xenografts in 
mice were used [32, 100].  In this paper, we focused on gene expression relating to the 
NRF2 network and downstream targets, as well as the glutathione and epigenetics 
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signatures, which are modulated by the anti-HER2 therapies. Different visualization 
methods were used to represent the results of statistical analysis of expression data. In 
addition to typical clustering of expression data in the form of heatmaps, we generated 
and analyzed volcano plots, Venn diagrams and signaling network maps. Volcano plots 
represent fold change in gene expression level together with the statistical significance of 
this change [32, 100, 101]. Signaling network maps combine gene expression data with 
protein signaling network downloaded from the KEGG database 
(http://www.genome.jp/kegg/ ), the work of Papp D et al, 2012 [102] and other 
knowledge-based approach and sources [103-106]. We used the R programming 
language for statistical processing of the data (Student's t-test) with the Bioconductor 
package for processing the data and Cytoscape (http://www.cytoscape.org ) with 
CytoKEGG plugin for network illustration to integrate the gene expression data with the 
KEGG signaling networks and also the NRF2-related interactome and regulome [102], 
downloaded and imported into the network model to Cytoscape. From there, the list of 
genes associated with the pathways were extracted and used in R to obtain the required 
gene expression values for further analysis. The means of the expression values in drug 
and control samples were calculated and followed by a Student's t-test to calculate the p-
values for the fold changes. We then generated the heatmaps showing the log2 fold-
change that the drugs caused to expression of the genes. We also used the fold-change 
data and the p-values to create volcano plots for the different drugs treatments using all 
the genes in the dataset and only for the genes associated with the different pathways 
examined and reported. Lastly, the ratios were exported to Cytoscape to color the nodes 
in the network visualization. 
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ABBREVIATIONS 
 
5-Aza: 5-azacytidine 
AR: Antioxidant Response  
ARE: Antioxidant Response Element 
DCFDA: 2′,7′-Dichlorofluorescin diacetate 
FBS: Foetal bovine serum 
GSH: Glutathione  
HDAC: Histone deacetylase  
HER: Human epidermal growth factor receptor 
HRG: Heregulin-β1 
KEAP1: Kelch-like ECH-associated protein 1 
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NAC: N-Acetyl Cysteine 
NRF2: Nuclear erythroid related factor-2 
RA: All-trans Retinoic acid 
ROS: Reactive oxygen species 
RTK: Receptor tyrosine kinase 
TSA: Trichostatin   
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Main Figure Legends 
 
Figure 1: Treatment with HER2 targeting antibodies generates Reactive Oxygen 
Species (ROS) that when neutralized leads to cytoprotection in ovarian cancer cells. 
(A) Heregulin treatment causes persistent elevation of ROS in ovarian cancer cells. 
Exponentially growing cells were seeded in triplicates in opaque flat bottom black walled 
96-well plates for 24 h. Following this, cells were either left untreated (UT) or treated 
with 1nM Heregulin for different time points as indicated. Following incubations, cells 
were loaded with DCFDA fluorescent stain for 45 min and assayed for ROS as described 
in Materials and Methods (B) HER2 targeting monoclonal antibodies cause ROS 
generation. Cells were seeded as in (A) and treated with either 1nM HRG alone or with 
co-treatment of 20µg/mL Pertuzumab (PR), Trastuzumab (TR) or their combination 
(COMB) for different time points as indicated and ROS assay was repeated. For both (A) 
and (B), the fluorescence reading recorded from each well was normalized to total cell 
abundance within the same wells as described in Materials and Methods. (C) Treatment 
with N-Acetyl Cysteine (NAC) desensitizes ovarian cells to immunotherapeutic agents 
targeting HER2. Cells were seeded as in (A) and either left untreated in media containing 
1nM Heregulin (HRG) or treated with same media containing 20µg/mL of HER2 
inhibitors, Pertuzumab and Trastuzumab either alone or in combination (RTKi only 
group) or in the continuous presence of 10mM NAC (RTKi + NAC group). Cells were 
treated with the MTT reagent as described in Materials and Methods and OD readings 
were obtained. Data shown are mean values ± S.D of triplicates, normalized to UT in (A) 
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or HRG in (B) and (C) and expressed as fold change. Statistical significance was 
determined between treatment groups either by independent t test or ONE WAY 
ANOVA followed by post hoc Tukey’s test as appropriate and significance expressed 
according to the scale * P <0.05, **P <0.01, ***P <0.001.  
 
Figure 2: Treatment with Retinoic acid (RA) causes inhibition of NRF2 dependent 
antioxidant response pathway and generates ROS. (A) Western analysis showing 
repression of NRF2 levels following RA treatment in PEO4, OVCAR4 and SKOV3 cell 
lines. Exponentially growing cells were either left untreated, treated with 2.5µM RA or  a 
combination of 2.5µM RA together with 20µg/mL of Pertuzumab and Trastuzumab for 
96 h before being harvested to prepare protein lysates and processed as described in 
Materials and Methods. Ponceau stain of the same blot was used as loading control. Red 
bars indicate NRF2 levels following quantification of immunoblot signal intensities 
obtained in (A) and normalized to the value of UT and expressed as fold change. The 
signal intensities of bands were quantified through integrated optical densitometry 
measurement.  (B) RA treatment causes inhibition of NRF2 dependent transcription. 
Exponentially growing AREc32 cell line stably expressing 8xcis-antioxidant response 
elements driving the expression of luciferase gene in an NRF2 dependent manner were 
either left untreated (UT), treated with RA alone, or with RA and combination of 
Pertuzumab and Trastuzumab for different time points as indicated. Following this, cell 
lysates were prepared and assayed for Luciferase activity (BrightGlo Luciferase system, 
Promega). Data are the mean values ± S.D of quadruplicates, normalized to untreated 
(UT) and expressed as fold change with statistical significance determined by ONE WAY 
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ANOVA followed by Tukey’s post hoc test according to the scale * P <0.05, **P <0.01, 
***P <0.001. (C) RA treatment causes repression of HO-1 levels. Immunofluorescent 
labelling of endogenous HO-1 in cells previously grown on poly-L lysine coated 
coverslips and exposed to RA treatment as in (A). For immunolabelling, primary HO-1 
antibody followed by Alexa Fluor® 568 conjugated secondary antibody (red 
fluorescence) was used. Nuclear reference was provided by co-staining with 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica 
DMiRe2 electronic microscope using integrated features of ANDOR iQ core software 
(ANDOR Technologies Ltd). Scale bar indicates 10µm. These are representative images 
taken in different field of views with relevant fluorescence channels and 100x objective.  
Figure 3: Inhibition of NRF2 pathway by Retinoic acid (RA) sensitizes ovarian 
cancer cells to immunotherapeutic agents targeting HER2 by increased ROS and 
enhanced growth inhibition. (A) RA treatment causes increase in ROS levels. 
Exponentially growing cells were seeded in triplicates in opaque flat bottom black walled 
96-well plates for 24 h. Following this, cells were either left untreated (UT) or treated 
with 1nM Heregulin and exposed to 2.5µM RA for different time points as indicated. 
Following incubations, cells were loaded with DCFDA fluorescent stain for 45 min and 
assayed for ROS by measuring fluorescence as described in Materials and Methods. Data 
is shown as fold change of RA treated cells to UT or RA and HRG treated cells to HRG 
treated cells as indicated (broken line). (B) Green fluorescent signal of DCFDA stain 
indicating ROS accumulation in ovarian cancer cells. Exponentially growing cells were 
either left untreated in media containing 1nM Heregulin (HRG) in the presence 5% 
charcoal stripped FBS, or treated with same media containing 20µg/mL of HER2 
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inhibitors, Pertuzumab and Trastuzumab either alone or in combination (RTKi only 
group) or in the continuous presence of 2.5µM RA (RTKi + RA group).Following 
treatments, cells were washed with PBS and imaged using Leica DMiRe2 electronic 
microscope and 485/535nm filter set. Merging with bright field phase contrast images 
captured in same field of view were performed by using integrated features of ANDOR 
iQ core software (ANDOR Technologies Ltd). Scale bar indicates 50µm. These are 
representative images with a 40x objective. (C) Growth inhibition measured using the 
MTT assay as described in Materials and Methods. Values are mean values ± S.D of 
triplicates and expressed as fold decrease to HRG. Statistical significance was determined 
between pairs of RTKi only and RTKi + RA groups by independent t test and 
significance expressed according to the scale * P <0.05, **P <0.01, ***P <0.001. 
 
Figure 4: Treatment with Pertuzumab and Trastuzumab causes repression of NRF2 
dependent transcription and depletion of total Glutathione levels (A) Combination of 
Pertuzumab and Trastuzumab cause inhibition of NRF2 dependent transcription. 
Exponentially growing AREc32 cell line stably expressing  cis-regulatory antioxidant 
response elements driving the expression of luciferase gene in an NRF2 dependent 
manner were treated with 1nM HRG alone or with co-treatment of 20µg/mL Pertuzumab 
and Trastuzumab either individually or in combination for different time points as 
indicated. Following this, cell lysates were prepared and assayed for Luciferase activity 
as described in Materials and Methods. Data shown are mean values ± S.D of 
quadruplicates, normalized to untreated (UT) and expressed as fold change with 
statistical significance determined by ONE WAY ANOVA followed by Tukey’s post hoc 
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test. In upper panel, asterisks indicate significant difference in inhibition between 
monotherapy and combination while the # notation indicates the significant difference of 
inhibition between HRG and all the treatment types. In lower panel, asterisks indicate 
significant differences between individual groups as indicated and according to the scale 
* P <0.05, **P <0.01, ***P <0.001. (B) Combination of targeted immunotherapeutic 
agents causes glutathione depletion. Exponentially growing cells were seeded in 60mm 
tissue culture plates for 24 h and either left untreated (UT) or treated with media 
containing 1nM Heregulin alone (HRG) or with co-treatment of 20µg/mL Pertuzumab 
(PR), Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested to 
prepare protein lysates and processed for glutathione assay. Data were normalized to the 
total protein content from same plates determined by Bradford assay and are mean values 
± S.D of triplicates and expressed as fold change to the UT. Statistical significance was 
determined by ONE WAY ANOVA followed by Tukey’s post hoc test according to the 
scale * P <0.05, **P <0.01, ***P <0.001. 
  
Figure 5: Treatment with Trastuzumab and/or Pertuzumab causes cytotoxicity and 
modulates expression of pHER2, pAKT, NRF2 and KEAP1 in ovarian cancer cell 
lines. (A) Effect of antibodies on cell number. Cells were treated with Pertuzumab (PR), 
Trastuzumab (TR) or combination (COMB) of antibodies in the presence of 1nM 
Heregulin. Antibodies were used at 20µg/mL. After  treatment, cell number was assessed 
by use of the MTT assay as described in Materials and Methods. Values are means with ± 
S.D of triplicates and expressed as fold decrease to HRG alone. Statistical significance 
was determined between untreated and treated groups by ONE WAY ANOVA followed 
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by Tukey’s post hoc test. Asterisks indicate significance of difference between HRG and 
individual treatment group whereas “#” indicates significance of difference between 
combination and Pertuzumab (red sign) or combination and Trastuzumab (blue sign) 
according to the scale * P <0.05, **P <0.01, ***P <0.001. (B) Western blot analysis 
showing levels of phospho HER2 T877 and phospho AKT S487 and (C) NRF2 and 
KEAP1 in response to treatments with 20µg/mL of Pertuzumab (Pr), Trastuzumab (Tr) 
and their combination (Comb) in PEO4, OVCAR4 and SKOV3 cells. Exponentially 
growing cells were treated with media containing 1nM Heregulin alone, or with co-
treatment of Pertuzumab, Trastuzumab or their combination for 96h before being 
analyzed as described in Materials and Methods. The bar charts show phospho HER2 or 
NRF2 (red bars) and phospho AKT levels or KEAP1 (blue bars) following quantification 
of the immunoblot signal intensities obtained and normalized to HRG treatment group 
and expressed as fold change. The signal intensities of bands were quantified through 
integrated optical densitometry measurement using Gelpro software (Version 3.1, Media 
Cybernetics).  
 
Figure 6. NRF2 network dependent molecular responses to Trastuzumab and 
Pertuzumab alone or in combination. (A) Heatmap showing significant (p=0.001) 
differential expression of genes within the NRF2 network relative to control treatment of 
SKOV3 ovarian xenograft tumors (SAM FDR=10%) as in References [15, 48]. Red 
represents increased expression and green decreased expression relative to the median of 
the controls. (B-D) Volcano-plots showing gene expression changes within the NRF2 
network following Trastuzumab (B), Pertuzumab (C), and their combination (D) 
treatment of the SKOV3 xenograft tumors. The genes with significant (p ≤ 0.05) and non-
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significant fold changes are colored red and black, respectively, while some genes with a 
high fold change are marked by blue crosses. (E-F) Venn diagram showing distinct and 
overlap of significantly up-regulated (E) and down-regulated (F) transcripts of genes 
within the NRF2 network relative to control treatment of SKOV3 xenograft tumors with 
Trastuzumab and Pertuzumab alone or in combination.  
Figure 7. Common and differential expression changes in transcription and 
epigenetics associated genes in responses to Trastuzumab and Pertuzumab alone or 
in combination of. (A) Heatmap showing differential changes (B) Heatmap showing 
significant (p≤0.05) differential changes in the expression of the genes relative to control 
treatment of SKOV3 ovarian xenograft tumors (SAM FDR=10%) as in References [15, 
48]. Red represents increased expression and green decreased expression relative to the 
median of the controls. (C-D) Volcano-plots showing gene expression changes in 
transcription and epigenetics associated genes following trastuzumab (C), pertuzumab 
(D), and their combination (E) treatment of the SKOV3 xenograft tumors. The genes with 
significant (p ≤ 0.05) and non-significant fold changes are colored red and black, 
respectively, and some genes with a high fold change are marked by blue crosses.  
 
Figure 8. Visualization of common and differential gene expression changes within 
the NRF2 network and signaling pathways. Network of gene expression profiles in 
response to either Trastuzumab (A) or Pertuzumab (B) alone, or following their 
combination treatment (C) in SKOV3 xenograft tumors from References [15, 48], , and 
as depicted in the NRF2-related interactome and regulome model of Papp D et al 2012 
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[50]. The color of the node depicts the ratio of the expression values with drug compared 
to the expression values in control samples. 
 
Figure 9: qRT PCR analysis of NRF2 and its substrates reveal downregulation of 
NRF2, HO-1 and GCLM mRNA expression following treatment with targeted 
immunotherapeutic agents. (A) Ovarian cancer cell lines exhibit different basal levels 
of NRF2 and its substrate expression. Exponentially growing cells were treated with 1nM 
Heregulin for 96 h. Following this, cells were harvested for total RNA for subsequent 
reverse transcription to generate cDNA and used to perform quantitative Real Time PCR 
(qRT PCR) as described in Materials and Methods. (B) Treatment with combination of 
Pertuzumab and Trastuzumab causes downregulation of NRF2, HO-1 and GCLM 
mRNA. Cells were exposed to combination of 20µg/mL of Pertuzumab and Trastuzumab 
for 96 h before being harvested for RNA and subjected to qRT PCR as in (A). (C) 
Luciferase reporter assay for NRF2 transcription demonstrates repression of NRF2 
transcription following exposure to HER2 targeting immunotherapeutic agents. 
Exponentially growing PEO4 and SKOV3 cells were transfected with either empty PGL3 
basic vector or 1µg PGL3 basic vector with cloned 1.5kb fragment of NRF2 promoter 
(prNRF2) driving the expression of luciferase gene. Co-transfection with 0.2µg pRL-
CMV plasmid was performed as an internal transfection control as described in the 
Materials and Methods. At 24 h post-transfection, cells were either left untreated in 
media containing 1nM HRG (UT) or treated with combination of 20µg/mL of 
Pertuzumab and Trastuzumab (COMB) for 96 h. Following treatments, cell lysates were 
prepared from the transfected cells, transferred to opaque flat bottom white 96-well plates 
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and their luciferase activity recorded using Dual luciferase reporter assay (Promega) in 
multiplate luminometer (MODULUSTM, Promega). For (A), (B) and (C), data are means 
with ± S.D of triplicates and expressed as fold change with statistical significance 
determined by either ONE WAY ANOVA or independent t test as appropriate according 
to the scale * P <0.05, **P <0.01, ***P <0.001. 
 
Figure 10: Treatment with HER2 targeting immunotherapeutic agents causes 
induction of HDAC1 expression and repression in phospho-HDAC levels. (A) 
Immunoblotting analysis showing induction of total HDAC 1 levels following treatment 
with combination of Pertuzumab and Trastuzumab in PEO4, OVCAR4 and SKOV3 cell 
lines. Exponentially growing cells were either left untreated (UT) or treated with media 
containing 1nM Heregulin alone (HRG), or with co-treatment of 20µg/mL of Pertuzumab 
(PR), Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested 
for immunoblotting using an anti-HDAC1 antibody (Table 1). Ponceau stain of the same 
blot was used as loading control Red bars indicate HDAC1 levels following 
quantification of the immunoblot signal intensities obtained and normalized to the value 
of UT and expressed as fold change. The signal intensities of bands were quantified as 
described in Materials and Methods, (B) Treatment with HER2 inhibitors causes 
induction of nuclear HDAC1 levels. Immunofluorescent labelling of endogenous HDAC1 
in cells previously grown on poly-L lysine coated coverslips and exposed to treatments as 
in (A). For immunolabelling, Alexa Fluor® 568 conjugated secondary antibody (red 
fluorescence) was used. Nuclear reference was provided by co-staining with 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica 
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DMiRe2 electronic microscope using integrated features of ANDOR iQ core software 
(ANDOR Technologies Ltd). Scale bar indicates 10µm. These are representative images 
taken in different field of views with relevant fluorescence channels and 100x objective. 
(C) Immunoblotting analysis of phospho-HDAC  levels following treatment with 
combination of Pertuzumab and Trastuzumab in PEO4, OVCAR4 and SKOV3 cell lines. 
Exponentially growing cells were either left untreated (UT) or treated with media 
containing 1nM Heregulin alone (HRG), or with co-treatment of 20µg/mL of Pertuzumab 
(PR), Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested to 
prepare protein lysates and processed for immunoblotting using an anti-phospho HDAC 
antibody (Table 1). Ponceau stain of the same blot was used as loading control (not 
shown). Red bars indicate phospho-HDAC levels following quantification of the 
immunoblot signal intensities obtained in (A) and normalized to the value of UT and 
expressed as fold change. The signal intensities of bands were quantified through 
integrated optical densitometry measurement as described in Materials and Methods 
 
Figure 11: Inhibition of HDAC and DNA Methyl Transferase induce NRF2 protein 
levels, causes nuclear localization of NRF2 and HO-1, disrupts both targeted 
immunotherapy dependent NRF2 protein and transcriptional repression, and 
activates NRF2 dependent antioxidant transcriptional response program. (A) 
Immunoblotting analysis showing induction of total NRF2 levels following treatment 
with combination of Trichostatin and 5-azacytidine both in the absence and presence of 
HER2 inhibitors. Exponentially growing cells were either left untreated in media 
containing 1nM Heregulin alone (UT) or treated with either a combination of 20µg/mL 
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Pertuzumab and Trastuzumab (COMB), with combination of 200nM Trichostatin A and 
2µM 5-Azacytidine (T/A) or with all four drugs together for 96 h. Following incubation, 
cells were harvested to prepare protein lysates and processed for immunoblotting using 
relevant antibodies (Table 1). Blotting with -actin was used as loading control. Red bars 
indicate NRF2 levels following quantification of the immunoblot signal intensities 
obtained in (A) and normalized to the value of UT and expressed as fold change. The 
signal intensities of bands were quantified through integrated optical densitometry 
measurement using Gelpro software (Version 3.1, Media Cybernetics). (B) Treatment 
with T/A causes nuclear induction of NRF2 and HO-1 levels. Immunofluorescent 
labelling of endogenous NRF2 (upper panels) and HO-1 (lower panels) in cells 
previously grown on poly-L lysine coated coverslips and exposed to T/A treatments as in 
(A). For immunolabelling, Alexa Fluor® 488 conjugated secondary antibody was used 
for NRF2 staining (green fluorescence), while Alexa Fluor® 568 conjugated secondary 
antibody was used for HO-1 staining (red fluorescence). Nuclear reference was provided 
by co-staining with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images 
were captured with Leica DMiRe2 electronic microscope, while merging, co-localization 
and further analysis were performed by using integrated features of ANDOR iQ core 
software (ANDOR Technologies Ltd). Scale bar indicates 10µm. These are 
representative images taken in different field of views with relevant fluorescence 
channels and 100x objective. (C) Inhibition of HDAC and DNA Methyl Transferase 
disrupt the transcriptional inhibition of NRF2 exerted by the HER2 targeting 
immunotherapeutic agents. Exponentially growing PEO1 and SKOV3 cells were seeded 
in triplicates in 24 well plates and transfected with either empty PGL3 basic vector or 
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1µg PGL3 basic vector with cloned 1.5kb fragment of NRF2 promoter (prNRF2) driving 
the expression of luciferase gene. Co-transfection with 0.2µg pRL-CMV plasmid was 
performed as an internal transfection control. At 24 h post-transfection, cells were either 
left untreated in media containing 1nM HRG (UT) or treated with combination of 
20µg/mL of Pertuzumab and Trastuzumab (COMB), or combination of 200nM 
Trichostatin A and 2µM 5-Azacytidine (T/A) or combination of COMB and T/A as 
indicated for 96 h. Following treatments, cell lysates were prepared from the transfected 
cells, transferred to opaque flat bottom white 96-well plates and their luciferase activity 
recorded using Dual luciferase reporter assay (Promega) in multiplate luminometer 
(MODULUSTM, Promega). (D) Inhibition of HDAC1 and DNA Methyl Transferases 
induce NRF2 dependent antioxidant transcriptional program. Exponentially growing 
AREc32 cell line stably expressing NRF2 dependent 8xcis- regulatory antioxidant 
response elements were seeded in triplicates in opaque 96 well plates and either mock 
treated (DMSO) or exposed individually to either 50µM tert-butylhydroquinone (tBHQ), 
5µM Sulforophane (Sul), 5µM Trichostatin (TSA), 5µM 5-azacytidine (5-Aza), or a 
combination of tBHQ with either TSA or 5-Aza, or a combination of Sul with TSA or 5-
Aza for 24 h. Following this, cell lysates were prepared and assayed for Luciferase 
activity (BrightGlo Luciferase system, Promega). For (C) and (D), Data are the means 
with ± S.D of triplicates and expressed as fold change with statistical significance 
determined by ONE WAY ANOVA followed by Tukey’s post hoc test according to the 
scale * P <0.05, **P <0.01, ***P <0.001. 
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Figure 12: Combination of HER2 targeting immunotherapeutic agents, Pertuzumab 
and Trastuzumab cause hypermethylation of NRF2 promoter Exponentially growing 
PEO4, OVCAR4 and SKOV3 cell lines were seeded in 60mm tissue culture plates and 
either left untreated in media containing 1nM HRG, or treated either individually or in 
combination with 20µg/mL of Pertuzumab and Trastuzumab for 96 h. Following this, 
cells were harvested for total genomic DNA, bisulfite converted, quantified and subjected 
to PCR using specific primers flanking the predicted CpG methylation sites in NRF2 
promoter. PCR products were sequenced, analyzed and examined for conserved CpG 
dinucleotides indicating methylation.  
Supplementary Figure legends 
 
Figure S1: Proliferation of ovarian cancer cell lines in absence or presence of either 
NAC or RA in growth media. Exponentially growing cells were seeded in 96 well 
plates in triplicates and allowed to attach for 24 h. Following this, cells were either left 
untreated (UT) in media containing 5% charcoal stripped FBS, or treated with same 
media containing 1nM Heregulin (HRG) or with cotreatments of 10mM NAC or 2.5µM 
RA individually for the indicated time points. MTT reagent was directly added at the end 
of treatments and cells further incubated for 4 h. The up taken dye was released by 
adding 100µL of DMSO for 15min and recording absorbance at 540nm using multiplate 
reader (MODULUSTM, Promega). Values are means with ± S.D of triplicates and 
expressed as fold decrease to UT alone.  
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Figure S2: Treatment with Retinoic acid (RA) causes elevation of Reactive Oxygen 
Species. Exponentially growing cells were seeded in triplicates in opaque flat bottom 
black walled 96-well plates for 24 h. Following this, cells were either left untreated in 
media containing 1nM Heregulin (UT) or exposed to 2.5µM RA, or cotreated with 
2.5µM RA and 20µg/mL of Pertuzumab and Trastuzumab for the indicated time points. 
Following incubations, cells were loaded with DCFDA fluorescent stain for 45 min and 
assayed for ROS by measuring fluorescence using fluorescence multiplate reader 
(MODULUSTM, Promega) with excitation and emission spectra of 485nm/535nm. Data 
are the means with ± S.D of triplicates and expressed as fold change with statistical 
significance determined by ONE WAY ANOVA followed by Tukey’s post hoc test 
according to the scale * P <0.05, **P <0.01, ***P <0.001. 
 
Figure S3: NRF2 promoter methylation profiling. (A) Prediction of methylated CpG 
dinucleotides in NRF2 promoter. Methprimer (www.urogene.org) was used to analyses 
1.5kb NRF2 promoter region for potential CpG islands and methylation prediction. A 
270pb stretch of promoter containing 18 CpG dinucleotides was identified for subsequent 
methylation analysis. (B) Agarose gel image of the PCR products from bisulfite 
converted DNA using bisulfite conversion specific primers. Total genomic DNA was 
extract from PEO4, OVCAR4 and SKOV3 cells previously either untreated (UT) or 
exposed to HER2 inhibitors (RTKi) for 96 h. The extracted DNA was quantified, 
bisulfite converted and subjected to PCR amplification using primers specific to the 
bisulfite converted DNA and flanking the 270pb region of NRF2 promoter containing the 
identified 18 CpG dinucleotides.  
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Tables 
 
Table 1: Antibodies used in the study 
 
Antibody Host 
Catalogue 
Number 
Company 
NRF2 Rabbit Sc-722 Santa Cruz 
KEAP1 Rabbit 4678S Cell signalling 
Phospho Her2 T877 Rabbit 2241S Cell signalling 
Phospho AKT 473 Rabbit 4060S Cell signalling 
HDAC1 Mouse 5356 Cell signalling 
PhosphoHDAC Rabbit 3443 Cell signalling 
Heme Oxygenase 1 (HO-1) Rabbit sc-10789 Santacruz 
Alexa fluor 488 conjugated 
secondary antibody 
Rabbit ab150077 Abcam 
Alexa fluor 568 conjugated 
secondary antibody 
Rabbit ab175471 Abcam 
β-actin Rabbit ab1801 Abcam 
Table 2: Primer sequences 
 
Primers Sequence 
Biseq forward 
Biseq reverse 
 
 
prNRF2 forward 
prNRF2 reverse 
 
 
GCLC F forward 
GCLC R reverse 
 
 
Probe 
 
5- TGAGATAAAAGTAGGGTAAGGTTTTGTA-3 
5- ACTACCAACTAAAATCCCAACAAAC-3 
 
 
5- CTC GAG GGC GTT GAT TGC TAT AGT CAG G-3 
5- CCA TGG GAT GAG CTG TGG ACC GTG TG-3 
 
 
5-TCTCTAATAAAGAGATGAGCAACATGC-3 
5-TTGACGATAGATAAAGAGATCTACGAA-3 
 
 
5FAM-CAGGAGATGATCAATGCCTTCCTGCAAC-3BHQ 
 
 
Table 3: Conserved CpG dinucleotides demonstrating methylated cytosines 
 
Cell Line Conserved CpG dinucleotides 
 UT Position Treated Position * 
PEO4 1 206 6 46, 79, 159, 163, 
184, 206 
OVCAR4 0 - 3 138, 184, 206 
SKOV3 0 - 1 157 
* Nucleotide position within the 270bp CpG island in NRF2 promoter (see fig. 15).  
 
 
